tetano
Editor, Senior Moderator
Cureus
. 2021 Dec 12;13(12):e20364.
doi: 10.7759/cureus.20364. eCollection 2021 Dec.
Long-Term Follow-Up of a Severe Eosinophilic Asthmatic Patient With Comorbid Nasal Polyposis Hospitalized for SARS-CoV-2 Infection While Receiving Benralizumab: A Case Report
Annamaria Ambrosino[SUP] 1 [/SUP]
Affiliations
Abstract
We report a case of a patient affected by severe eosinophilic asthma with nasal polyps (SEA+NP) who developed coronavirus disease 2019 (COVID-19) six months after starting benralizumab as add-on therapy. Both SEA and NP were under control with no exacerbations at the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The patient was hospitalized for four months, during which the treatment with benralizumab was interrupted. Despite the onset of bilateral interstitial pneumonia, developed as a consequence of the SARS-CoV-2 infection, the patient was discharged without complications, with a significant improvement in the chest CT scan following the administration of systemic corticosteroids (SCS) and low-flow oxygen therapy. The treatment with benralizumab was reintroduced at the regular dosing regimen immediately after his discharge. Lung function was assessed three months after the discharge and showed normal levels as before the development of COVID-19 symptoms. A long-term follow-up after 26 months from the introduction of benralizumab showed a normal lung function and well-controlled asthma, without exacerbations or the need for corticosteroid bursts.
Keywords: "anti il5-r"; "covid-19" "severe eosinophilic asthma" "nasal polyps" "benralizumab" "interstitial pneumonia"; "emergency visit" "spirometry" "biologic" "long term follow up"; emergency medical service; long term follow up.
. 2021 Dec 12;13(12):e20364.
doi: 10.7759/cureus.20364. eCollection 2021 Dec.
Long-Term Follow-Up of a Severe Eosinophilic Asthmatic Patient With Comorbid Nasal Polyposis Hospitalized for SARS-CoV-2 Infection While Receiving Benralizumab: A Case Report
Annamaria Ambrosino[SUP] 1 [/SUP]
Affiliations
- PMID: 35036198
- PMCID: PMC8752115
- DOI: 10.7759/cureus.20364
Abstract
We report a case of a patient affected by severe eosinophilic asthma with nasal polyps (SEA+NP) who developed coronavirus disease 2019 (COVID-19) six months after starting benralizumab as add-on therapy. Both SEA and NP were under control with no exacerbations at the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The patient was hospitalized for four months, during which the treatment with benralizumab was interrupted. Despite the onset of bilateral interstitial pneumonia, developed as a consequence of the SARS-CoV-2 infection, the patient was discharged without complications, with a significant improvement in the chest CT scan following the administration of systemic corticosteroids (SCS) and low-flow oxygen therapy. The treatment with benralizumab was reintroduced at the regular dosing regimen immediately after his discharge. Lung function was assessed three months after the discharge and showed normal levels as before the development of COVID-19 symptoms. A long-term follow-up after 26 months from the introduction of benralizumab showed a normal lung function and well-controlled asthma, without exacerbations or the need for corticosteroid bursts.
Keywords: "anti il5-r"; "covid-19" "severe eosinophilic asthma" "nasal polyps" "benralizumab" "interstitial pneumonia"; "emergency visit" "spirometry" "biologic" "long term follow up"; emergency medical service; long term follow up.